Independent French drugmaker Servier has agreed to buy the Danish antibody discovery company Symphogen.
The acquisition is the result of a process that has apparently been underway for several months, and the companies had been engaged in an immuno-oncology collaboration for more than two years.
"This acquisition will boost significantly our R&D in oncology and in our other therapeutic areas"Servier has said that it will strengthen its antibody capabilities and secure its ambition to become a recognized player in oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze